PMID- 28635789
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20191120
IS  - 1997-7298 (Print)
IS  - 1997-7298 (Linking)
VI  - 115
IP  - 6. Vyp. 2
DP  - 2015
TI  - [Pharmacotherapy accompanied by deep brain stimulation of the subthalamic nucleus 
      in patients with Parkinson's disease].
PG  - 73-78
LID - 10.17116/jnevro20151156273-78 [doi]
AB  - AIM: To analyze pharmacotherapy accompanied by deep brain stimulation of the 
      subthalamic nucleus. MATERIAL AND METHODS: The study included 54 patients, who 
      underwent bilateral STN DBS from 2003 to 2012. The severity of motor 
      disturbances, activities of daily living and complications of dopaminergic 
      therapy were estimated in accordance with II, III and IV parts of the Unified 
      Parkinson's Disease Rating Scale (UPDRS) before operation and one, three and four 
      years after it. L-dopa equivalent daily dose (LEDD) was assessed along with an 
      analysis of the pharmacotherapy in whole. RESULTS AND CONCLUSION: By the end of 
      the 1st year, the severity of motor disturbances in OFF-period decreased by 52.3% 
      and remained stable for 3 years (51.8%), a slight increase of severity of motor 
      disturbances was observed later, however it didn't reach the pre-operative level. 
      The severity of motor fluctuations and drug-induced dyskinesia fell by 64.9%, 
      70.7% and 42.7% by the end of the first, third and fourth year of observation. 
      The maximal decrease in LEDD was reached by the end of the 1st year and accounted 
      for 57.7%; by the end of the third and fourth years it was 52.4% and 38.2%, 
      respectively. During the 1st year, 16.7% of patients didn't take levodopa. The 
      dose of pure levodopa decreased by the end of the 1st year by 64.6%, and by 56.7% 
      and 43.7% by the end of the 3rd and 4th years, respectively. Monotherapy by an 
      agonist of dopamine receptors (ADR) was received by 12.9% of patients, thus the 
      share of ADR as part of the combined therapy increased in the postoperative 
      period from 24.1% to 35.2%.
FAU - Bril, E V
AU  - Bril EV
AD  - Russian Medical Academy of Postgraduate Education, Moscow.
FAU - Tomskiy, A A
AU  - Tomskiy AA
AD  - Burdenko Research Institute of Neurosurgery, Moscow.
FAU - Gamaleya, A A
AU  - Gamaleya AA
AD  - Burdenko Research Institute of Neurosurgery, Moscow.
FAU - Poddubskaya, A A
AU  - Poddubskaya AA
AD  - Burdenko Research Institute of Neurosurgery, Moscow.
FAU - Fedorova, N V
AU  - Fedorova NV
AD  - Russian Medical Academy of Postgraduate Education, Moscow.
FAU - Gubareva, N N
AU  - Gubareva NN
AD  - Russian Medical Academy of Postgraduate Education, Moscow.
FAU - Dekopov, A V
AU  - Dekopov AV
AD  - Burdenko Research Institute of Neurosurgery, Moscow.
FAU - Shabalov, V A
AU  - Shabalov VA
AD  - Burdenko Research Institute of Neurosurgery, Moscow.
LA  - rus
PT  - English Abstract
PT  - Journal Article
TT  - Medikamentoznaia terapiia na fone elektrostimuliatsii subtalamicheskogo iadra u 
      patsientov s bolezn'iu Parkinsona.
PL  - Russia (Federation)
TA  - Zh Nevrol Psikhiatr Im S S Korsakova
JT  - Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
JID - 9712194
OTO - NOTNLM
OT  - L-dopa equivalent daily dose
OT  - Parkinson's disease
OT  - chronic bilateral deep brain stimulation of the subthalamic nucleus
OT  - drug-induced dyskinesia
OT  - motor fluctuations
EDAT- 2015/01/01 00:00
MHDA- 2015/01/01 00:01
CRDT- 2017/06/22 06:00
PHST- 2017/06/22 06:00 [entrez]
PHST- 2015/01/01 00:00 [pubmed]
PHST- 2015/01/01 00:01 [medline]
AID - 10.17116/jnevro20151156273-78 [doi]
PST - ppublish
SO  - Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6. Vyp. 2):73-78. doi: 
      10.17116/jnevro20151156273-78.